BioSpace News Archive

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, today announced the appointment of Alan Muney, MD to its Board of Directors.

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Phase 2 clinical trial evaluating DNA medicine INO-4800, its COVID-19 vaccine candidate,

Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced it has expanded its presence in the Dallas-Fort Worth metroplex through its partnership with Mesquite | DeSoto Dermatology.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s governance. Todd Schermerhorn has been appointed to the Board of Directors, effective December 3. Schermerhorn has 35 years of experience in global healthcare, including 27 years at C.R. Bard Inc. where he held various positions of increasing responsibility on the finance team, whic

Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets.

Exelixis, Inc. (Nasdaq: EXEL) and Aurigene today announced that Exelixis has exercised its exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102 (formerly AUR102).

A pair of the Pittsburgh region’s biggest boosters for the life sciences sector are taking their efforts to the next level, as LifeX Labs and Pittsburgh Life Science Greenhouse (PLSG) announced they are forming a strategic alliance to accelerate growth in the industry.

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, and 3D Medicines Inc. (“3DMed”), a China-based biopharmaceutical company developing next-generation immuno-oncology drugs,

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, announced the results of its 2020 Annual General Meeting, which was held on December 7, 2020, in Hong Kong S.A.R., China.

The Know Migraine Mission Initiative Seeks to Challenge Misconceptions and Start new Conversations About Migraine Karamo Brown to Connect Directly with People Affected by Migraine to Share Experiences and Advice During This Challenging Time COVID-19 has had a Significant Impact on People who Live With Migraine,(1) so it’s More Important Than Ever to Offer Compassion and Understanding Around the Disease